Pub Date : 2024-06-26DOI: 10.1016/j.bulcan.2024.04.015
Alexandra Nassar, Maria Conticchio, Marie-Julie Lardinois, Juliette Benedetti, Lisa Lartigau, Ugo Marchese, Stylianos Tzedakis, David Fuks
Benign tumors of the liver and biliary tract are rare entities, and some of them require surgical management to prevent their malignant transformation. Tumors from the biliary tract with malignant potential are treated either by hepatic resection, for mucinous cystic neoplasm and ciliated hepatic foregut cysts, or by biliary resections, for biliary papillary neoplasm and type I and IV choledochal cysts. The pathologies requiring prophylactic cholecystectomy are polyps larger than 10 mm, porcelain gallbladder and pancreaticobiliary maljunction. Finally, hepatocellular adenoma over 5cm, occurring in male patients, or exon 3 mutated beta-catenin, should lead to prophylactic resection by hepatic segmentectomy. This article describes these different pathologies and their management.
肝脏和胆道的良性肿瘤非常罕见,其中一些需要手术治疗,以防止恶变。对于有恶变可能的胆道肿瘤,可通过肝切除术治疗粘液性囊腺瘤和纤毛肝前肠囊肿,或通过胆道切除术治疗胆道乳头状瘤和 I 型及 IV 型胆总管囊肿。需要进行预防性胆囊切除术的病变是大于 10 毫米的息肉、瓷胆囊和胰胆管连接不良。最后,男性患者中出现的超过 5 厘米的肝细胞腺瘤或 beta-catenin 第 3 外显子突变,应通过肝段切除术进行预防性切除。本文介绍了这些不同的病理变化及其治疗方法。
{"title":"[Prophylactic surgery for hepatic and biliary tumors].","authors":"Alexandra Nassar, Maria Conticchio, Marie-Julie Lardinois, Juliette Benedetti, Lisa Lartigau, Ugo Marchese, Stylianos Tzedakis, David Fuks","doi":"10.1016/j.bulcan.2024.04.015","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.04.015","url":null,"abstract":"<p><p>Benign tumors of the liver and biliary tract are rare entities, and some of them require surgical management to prevent their malignant transformation. Tumors from the biliary tract with malignant potential are treated either by hepatic resection, for mucinous cystic neoplasm and ciliated hepatic foregut cysts, or by biliary resections, for biliary papillary neoplasm and type I and IV choledochal cysts. The pathologies requiring prophylactic cholecystectomy are polyps larger than 10 mm, porcelain gallbladder and pancreaticobiliary maljunction. Finally, hepatocellular adenoma over 5cm, occurring in male patients, or exon 3 mutated beta-catenin, should lead to prophylactic resection by hepatic segmentectomy. This article describes these different pathologies and their management.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-25DOI: 10.1016/j.bulcan.2024.04.014
Carole Farrugia, Alexandra Lhostette, Marion Brasseur, Thomas Biot, Hélène Calmes, Caroline Dendoncker, Anne Sophie Dupret, Sophie Estheve, Sylivie Filiol, Virginie Guidi, Lisa Hadrot, Manon Perez, Aurélie Ravinet, Laure Tardieu, Léonardo Magro, Serge Alfandari, Nicolas Simon, Sarah Guenounou, Jérôme Cornillon
The nutritional status after bone marrow transplant plays an important role in the outcome of patients. Post-allograft dietary instructions are therefore essential to ensure quality nutrition while minimizing the risk of infection. For patients, this is one of their main concerns on discharge from hospital. With the aim of harmonizing post-allograft dietary instructions, a multidisciplinary working group has been set up within a number of French centers performing hematopoietic stem cell allogenic transplantation. The dietary guidelines have been updated by this working group, through videoconference meetings, an online questionnaire, a review of the literature and deliberations at harmonization days. These instructions will be incorporated into the next update of the adult and pediatric post-transplant follow-up booklet.
{"title":"[Diet guidelines in adult and pediatric patient after allogeneic stem cell transplantation (SFGM-TC)].","authors":"Carole Farrugia, Alexandra Lhostette, Marion Brasseur, Thomas Biot, Hélène Calmes, Caroline Dendoncker, Anne Sophie Dupret, Sophie Estheve, Sylivie Filiol, Virginie Guidi, Lisa Hadrot, Manon Perez, Aurélie Ravinet, Laure Tardieu, Léonardo Magro, Serge Alfandari, Nicolas Simon, Sarah Guenounou, Jérôme Cornillon","doi":"10.1016/j.bulcan.2024.04.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.04.014","url":null,"abstract":"<p><p>The nutritional status after bone marrow transplant plays an important role in the outcome of patients. Post-allograft dietary instructions are therefore essential to ensure quality nutrition while minimizing the risk of infection. For patients, this is one of their main concerns on discharge from hospital. With the aim of harmonizing post-allograft dietary instructions, a multidisciplinary working group has been set up within a number of French centers performing hematopoietic stem cell allogenic transplantation. The dietary guidelines have been updated by this working group, through videoconference meetings, an online questionnaire, a review of the literature and deliberations at harmonization days. These instructions will be incorporated into the next update of the adult and pediatric post-transplant follow-up booklet.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-25DOI: 10.1016/j.bulcan.2024.02.006
Cécile Renard, Alizee Corbel, Catherine Paillard, Cécile Pochon, Pascale Schneider, Nicolas Simon, Nimrod Buchbinder, Mony Fahd, Ibrahim Yakoub-Agha, Charlotte Calvo
Treatment of pediatric high-risk acute myeloid leukemia (AML), defined either on molecular or cytogenetic features, relies on bone marrow transplant after cytologic remission. However, relapse remains the first post-transplant cause of mortality. In this 13th session of practice harmonization of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), our group worked on recommendations regarding the management of post-transplant relapse in AML pediatric patients based on international literature, national survey and expert opinion. Overall, immunomodulation strategy relying on both measurable residual disease (MRD) and chimerism evaluation should be used for high-risk AML. In very high-risk (VHR) AML with a 5-year overall survival ≤30 %, a post-transplant maintenance should be proposed using either hypomethylating agents, combined with DLI whenever possible, or FLT3 tyrosine kinase inhibitors if this target is present on leukemia cells. In the pre-emptive or early relapse settings (< 6 months post-transplant), treatments combining DLI, Azacytidine and Venetoclax should be considered. Access to phase I/II trails for targeted therapies (menin, IDH or JAK inhibitors) should be discussed in each patient according to the underlying molecular abnormalities of the disease.
{"title":"[Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)].","authors":"Cécile Renard, Alizee Corbel, Catherine Paillard, Cécile Pochon, Pascale Schneider, Nicolas Simon, Nimrod Buchbinder, Mony Fahd, Ibrahim Yakoub-Agha, Charlotte Calvo","doi":"10.1016/j.bulcan.2024.02.006","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.02.006","url":null,"abstract":"<p><p>Treatment of pediatric high-risk acute myeloid leukemia (AML), defined either on molecular or cytogenetic features, relies on bone marrow transplant after cytologic remission. However, relapse remains the first post-transplant cause of mortality. In this 13<sup>th</sup> session of practice harmonization of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), our group worked on recommendations regarding the management of post-transplant relapse in AML pediatric patients based on international literature, national survey and expert opinion. Overall, immunomodulation strategy relying on both measurable residual disease (MRD) and chimerism evaluation should be used for high-risk AML. In very high-risk (VHR) AML with a 5-year overall survival ≤30 %, a post-transplant maintenance should be proposed using either hypomethylating agents, combined with DLI whenever possible, or FLT3 tyrosine kinase inhibitors if this target is present on leukemia cells. In the pre-emptive or early relapse settings (< 6 months post-transplant), treatments combining DLI, Azacytidine and Venetoclax should be considered. Access to phase I/II trails for targeted therapies (menin, IDH or JAK inhibitors) should be discussed in each patient according to the underlying molecular abnormalities of the disease.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-24DOI: 10.1016/j.bulcan.2024.04.009
Florian Chevillon, Marine Rebotier, Nathalie Dhédin, Bénédicte Bruno, Carlotta Cacciatore, Amandine Charbonier, Laure Joseph, Amandine Le Bourgeois, Marie Talouarn, Leonardo Magro, Virginie Barraud Lange
Conditioning regimen prior to hematopoietic stem cell transplantation have an impact on patient fertility through the use of gonadal irradiation and/or bifunctional alkylating agents. Their impact on fertility depends mainly on the dose used and, in women, on age at the time of treatment. All patients should benefit before treatment from a consultation informing them of the potential impact on fertility and of fertility preservation techniques. In the absence of contraindications, the major toxicity of myeloablative conditioning regimen justifies fertility preservation. There are few data concerning fertility after reduced-intensity conditioning. Despite lower theoretical gonadotoxicity, we also recommend fertility preservation, if possible before transplantation. The fertility preservation techniques used depend on the patient's age, pathology and conditioning. In the event of subsequent use of harvested gonadal tissue in the context of acute leukemia or aggressive lymphoma, it is advisable to assess the risk of reintroduction of tumor cells. Finally, it is recommended to assess gonadal function after transplant, especially after reduced conditioning. If there is persistent residual gonadal function, post-treatment fertility preservation should be discuss.
{"title":"[Fertility preservation and hematopoietic stem cell transplantation (SFGM-TC)].","authors":"Florian Chevillon, Marine Rebotier, Nathalie Dhédin, Bénédicte Bruno, Carlotta Cacciatore, Amandine Charbonier, Laure Joseph, Amandine Le Bourgeois, Marie Talouarn, Leonardo Magro, Virginie Barraud Lange","doi":"10.1016/j.bulcan.2024.04.009","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.04.009","url":null,"abstract":"<p><p>Conditioning regimen prior to hematopoietic stem cell transplantation have an impact on patient fertility through the use of gonadal irradiation and/or bifunctional alkylating agents. Their impact on fertility depends mainly on the dose used and, in women, on age at the time of treatment. All patients should benefit before treatment from a consultation informing them of the potential impact on fertility and of fertility preservation techniques. In the absence of contraindications, the major toxicity of myeloablative conditioning regimen justifies fertility preservation. There are few data concerning fertility after reduced-intensity conditioning. Despite lower theoretical gonadotoxicity, we also recommend fertility preservation, if possible before transplantation. The fertility preservation techniques used depend on the patient's age, pathology and conditioning. In the event of subsequent use of harvested gonadal tissue in the context of acute leukemia or aggressive lymphoma, it is advisable to assess the risk of reintroduction of tumor cells. Finally, it is recommended to assess gonadal function after transplant, especially after reduced conditioning. If there is persistent residual gonadal function, post-treatment fertility preservation should be discuss.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.1016/j.bulcan.2024.05.001
Julie Audet, Marc Berger, Johanne Cashman, Yves Chalandon, Laure Coulombel, Stéphane Flamant, Saghi Ghaffari, Sylvain Lefort, François Lemoine, Véronique Maguer-Satta, Franck E Nicolini, Christian Schmitt, Ivan Sloma, Ali Turhan
{"title":"Pr Connie J. Eaves (1944–2024).","authors":"Julie Audet, Marc Berger, Johanne Cashman, Yves Chalandon, Laure Coulombel, Stéphane Flamant, Saghi Ghaffari, Sylvain Lefort, François Lemoine, Véronique Maguer-Satta, Franck E Nicolini, Christian Schmitt, Ivan Sloma, Ali Turhan","doi":"10.1016/j.bulcan.2024.05.001","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.05.001","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-15DOI: 10.1016/j.bulcan.2024.04.003
Perrine Côme, Pauline Rochefort, Lucas De Crignis, Aurélien Dupré
One to 3% of gastric cancers are secondary to genetic predisposition, notably hereditary diffuse gastric cancers (HDGC) caused by CDH1 gene mutations. According to French recommendations, in case of CDH1 gene mutation, a prophylactic total gastrectomy should be performed between 20 and 30 years old. This gastrectomy should remove all the gastric mucosa at both extremities (duodenal and esophageal sides). Histopathological examinations of prophylactic total gastrectomies in asymptomatic CDH1-mutated patients reveal microscopic foci of diffuse-type cancer in 90 to 100% of cases. Lymph node involvement and lympho-vascular invasion are extremely rare, justifying the use of a D1-only lymphadenectomy. In the context of prophylaxis, limited lymphadenectomy and the development of minimally invasive oesogastric surgery, the minimally invasive approach might be the preferred approach, in expert centers. Surgical outcomes seem to be similar to those after gastrectomy for cancer. Prophylactic total gastrectomy is the cornerstone of CGDH management, associated with multidisciplinary follow-up and mammary surveillance in women.
{"title":"[Prophylactic gastrectomy].","authors":"Perrine Côme, Pauline Rochefort, Lucas De Crignis, Aurélien Dupré","doi":"10.1016/j.bulcan.2024.04.003","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.04.003","url":null,"abstract":"<p><p>One to 3% of gastric cancers are secondary to genetic predisposition, notably hereditary diffuse gastric cancers (HDGC) caused by CDH1 gene mutations. According to French recommendations, in case of CDH1 gene mutation, a prophylactic total gastrectomy should be performed between 20 and 30 years old. This gastrectomy should remove all the gastric mucosa at both extremities (duodenal and esophageal sides). Histopathological examinations of prophylactic total gastrectomies in asymptomatic CDH1-mutated patients reveal microscopic foci of diffuse-type cancer in 90 to 100% of cases. Lymph node involvement and lympho-vascular invasion are extremely rare, justifying the use of a D1-only lymphadenectomy. In the context of prophylaxis, limited lymphadenectomy and the development of minimally invasive oesogastric surgery, the minimally invasive approach might be the preferred approach, in expert centers. Surgical outcomes seem to be similar to those after gastrectomy for cancer. Prophylactic total gastrectomy is the cornerstone of CGDH management, associated with multidisciplinary follow-up and mammary surveillance in women.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-15DOI: 10.1016/j.bulcan.2024.03.004
Maryse Karrer, Marie Bannier, Romain Arini, Christine Arnou, Joëlle André-Vert
{"title":"[Breast reconstruction: towards a better patient involvement for shared decision making after mastectomy].","authors":"Maryse Karrer, Marie Bannier, Romain Arini, Christine Arnou, Joëlle André-Vert","doi":"10.1016/j.bulcan.2024.03.004","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.03.004","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-15DOI: 10.1016/j.bulcan.2024.04.002
Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, Solène Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten
Haematopoietic stem cell collection from paediatric donors is a common and life-saving practice, as evidenced by the fact that there is a growing annual number of cases of transplants from minor donors among SFGM-TC centers over the last decade. Still, medical use of human tissue from a healthy and underage donor requires proper regulations and medical management. The guidelines below aim at underlining the importance of pondering the legal, medical and ethical aspects of using stem cells from healthy paediatric donors and stress out the importance of obtaining informed consent at the time of assessing HLA compatibility. Combined medical and psychological assessments are required before the donation, as well as one month later and one year later to ensure of the child's physical and mental wellbeing. Bone marrow harvest under general anaesthetics remains the preferred method of collection for children. Peripheral blood stem cell collection should only be considered for children who will not require a central venous access for collection. We aim at offering guidelines centered on the healthy child donating stem cells and his/her wellbeing, and these should be regularly reviewed as medical practices evolve.
{"title":"[Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)].","authors":"Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, Solène Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten","doi":"10.1016/j.bulcan.2024.04.002","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.04.002","url":null,"abstract":"<p><p>Haematopoietic stem cell collection from paediatric donors is a common and life-saving practice, as evidenced by the fact that there is a growing annual number of cases of transplants from minor donors among SFGM-TC centers over the last decade. Still, medical use of human tissue from a healthy and underage donor requires proper regulations and medical management. The guidelines below aim at underlining the importance of pondering the legal, medical and ethical aspects of using stem cells from healthy paediatric donors and stress out the importance of obtaining informed consent at the time of assessing HLA compatibility. Combined medical and psychological assessments are required before the donation, as well as one month later and one year later to ensure of the child's physical and mental wellbeing. Bone marrow harvest under general anaesthetics remains the preferred method of collection for children. Peripheral blood stem cell collection should only be considered for children who will not require a central venous access for collection. We aim at offering guidelines centered on the healthy child donating stem cells and his/her wellbeing, and these should be regularly reviewed as medical practices evolve.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.1016/j.bulcan.2024.03.007
François Guilhot
{"title":"[The need to set up a national register of adult cancers in France].","authors":"François Guilhot","doi":"10.1016/j.bulcan.2024.03.007","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.03.007","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141051898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.1016/j.bulcan.2024.04.002
Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, S. Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten
{"title":"[Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)].","authors":"Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, S. Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten","doi":"10.1016/j.bulcan.2024.04.002","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.04.002","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}